Temozolomide in children with recurrent or refractory central nervous system (CNS) tumours [Temozolomide bij kinderen met een gerecidiveerde of refractaire centraal zenuwstelsel tumor]
Completed
- Conditions
- Glioma high grade, primitive neuroectodermal tumour (PNET)CancerMalignant neoplasm of brain
- Registration Number
- ISRCTN16192422
- Lead Sponsor
- Dutch Childhood Oncology Group (Stichting Kinder Oncologie [SKION]) (The Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
1. Aged 3 - 18 years
2. Pathology: primitive neuroectodermal tumour (PNET)/high grade glioma
3. Measurable tumour
4. Lansky score greater than 50%
5. Expected life span of 12 weeks or more
6. Informed consent
Exclusion Criteria
Non-conformation to inclusion criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method